Back to top
more

Basilea Pharmaceutica (BPMUF)

(Delayed Data from OTC)

$47.00 USD

47.00
NA

0.00 (0.00%)

Updated Jul 17, 2024 02:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for BPMUF

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Basilea Pharmaceutica AG falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 72 91 164 178 132
Receivables 65 65 71 35 28
Notes Receivable 0 0 0 0 0
Inventories 29 25 25 23 19
Other Current Assets 4 3 4 3 7
Total Current Assets 169 184 264 238 186
Net Property & Equipment 4 4 2 3 5
Investments & Advances 0 0 0 0 30
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 1 1 1 1 0
Deposits & Other Assets 0 24 3 0 1
Total Assets 193 231 271 245 223
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 7 0 12 14 7
Current Portion Long-Term Debt 17 39 135 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 26 36 42 35 36
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 1 1 1 3 33
Total Current Liabilities 53 78 191 54 76
Mortgages 0 0 0 0 0
Deferred Taxes/Income 11 11 13 14 17
Convertible Debt 106 100 103 256 199
Long-Term Debt 0 38 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 17 9 27 30 25
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 204 253 335 354 316
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 15 14 14 13 12
Capital Surplus 1,161 1,087 1,127 1,048 933
Retained Earnings -1,115 -1,060 -1,120 -1,084 -1,008
Other Equity -11 -4 -24 -29 -25
Treasury Stock 60 59 62 56 6
Total Shareholder's Equity -11 -22 -64 -109 -94
Total Liabilities & Shareholder's Equity 193 231 271 245 223
Total Common Equity -11 -22 -64 -109 -94
Shares Outstanding 11.80 11.80 10.70 10.70 11.80
Book Value Per Share -0.94 -1.84 -5.99 -10.17 -7.93

Fiscal Year End for Basilea Pharmaceutica AG falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,999 -99,999 72 -99,999 -99,898
Receivables NA NA 65 NA 72
Notes Receivable NA NA 0 NA NA
Inventories NA NA 29 NA 29
Other Current Assets NA NA 4 NA 5
Total Current Assets NA NA 169 NA 207
Net Property & Equipment NA NA 4 NA 4
Investments & Advances NA NA 0 NA NA
Other Non-Current Assets NA NA 0 NA NA
Deferred Charges NA NA 0 NA NA
Intangibles NA NA 1 NA 1
Deposits & Other Assets NA NA 0 NA 25
Total Assets NA NA 193 NA 256
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA NA 0 NA NA
Accounts Payable NA NA 7 NA 4
Current Portion Long-Term Debt NA NA 17 NA 42
Current Portion Capital Leases NA NA 0 NA NA
Accrued Expenses NA NA 26 NA 25
Income Taxes Payable NA NA 0 NA NA
Other Current Liabilities NA NA 1 NA 1
Total Current Liabilities NA NA 53 NA 75
Mortgages NA NA 0 NA NA
Deferred Taxes/Income NA NA 11 NA 11
Convertible Debt NA NA 106 NA 106
Long-Term Debt NA NA 0 NA 20
Non-Current Capital Leases NA NA 0 NA NA
Other Non-Current Liabilities NA 17 NA 9
Minority Interest (Liabilities) NA NA 0 NA NA
Total Liabilities NA NA 204 NA 239
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA NA 0 NA NA
Common Stock (Par) NA NA 15 NA 15
Capital Surplus NA NA 1,161 NA 1,157
Retained Earnings NA NA -1,115 NA -1,090
Other Equity NA NA -11 NA -4
Treasury Stock NA NA 60 NA 62
Total Shareholder's Equity NA NA -11 NA 17
Total Liabilities & Shareholder's Equity NA NA 193 NA 256
Total Common Equity 0 0 -11 0 100,016
Shares Outstanding 11.80 11.80 11.80 11.80 11.80
Book Value Per Share 0.00 0.00 -0.94 0.00 8,475.90